Cancer Cachexia - Pipeline Insight, 2025
Description
DelveInsight’s, “Cancer Cachexia - Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Cancer Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cancer Cachexia: Overview
Cancer cachexia is an insidious syndrome that not only has a dramatic impact on patient quality of life, but is also associated with poor responses to chemotherapy and survival. Indeed, cachexia occurs in the majority of terminal cancer patients and, according to Warren, It is responsible for the death of 22% of cancer patients. It is a type of (wasting syndrome) a common complication of cancer that causes significant amounts of skeletal muscle and body fat loss.
Cancer cachexia can affect your quality of life and may affect the ability to receive cancer treatment. Its prevalence varies across cancer types, ranging from 87% in pancreatic and gastric cancer to 40% in breast cancer, sarcoma, leukemia, and Hodgkin lymphoma. As a secondary disease in cancer patients, cachexia progresses with systemic inflammation, negative protein-energy balance, and involuntary loss of lean body mass. These changes, accompanied by alterations in body composition, contribute to clinical manifestations such as significant weight reduction and disruptions in biological balance. Recognizing these symptoms is crucial for early intervention and management to improve patient outcomes.
Diagnosis typically involves assessing clinical signs such as weight loss exceeding 5% within six months, decreased food intake, reduced muscle strength, and overall decline in functional status. Laboratory tests may reveal abnormalities such as anemia, elevated inflammatory markers, and altered metabolic parameters. Imaging studies can identify tumor burden and potential complications. Importantly, diagnosis requires ruling out other causes of weight loss and muscle wasting. Once diagnosed, management involves a multidisciplinary approach focusing on symptom management, nutritional support, physical activity, and addressing underlying cancer pathology, aiming to improve quality of life and potentially treatment outcomes.
The treatment of cancer cachexia requires a comprehensive, individualized approach focused on improving muscle mass, enhancing overall body state, and increasing tolerance to anti-tumor therapies. While tumors continue to grow, cancer cachexia can be separated from underlying diseases through targeted blockade of cachexia signals, prolonging survival. Palliative treatment strategies are preferred for end-stage cachexia. In cases of catabolically active underlying diseases like advanced lung cancer and bile duct cancer, inhibiting catabolic drugs is the primary treatment choice.
""Cancer Cachexia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cancer Cachexia pipeline landscape is provided which includes the disease overview and Cancer Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cancer Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Cachexia Emerging Drugs
Further product details are provided in the report……..
Cancer Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
Cancer Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.
Cancer Cachexia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Cancer Cachexia: Overview
Cancer cachexia is an insidious syndrome that not only has a dramatic impact on patient quality of life, but is also associated with poor responses to chemotherapy and survival. Indeed, cachexia occurs in the majority of terminal cancer patients and, according to Warren, It is responsible for the death of 22% of cancer patients. It is a type of (wasting syndrome) a common complication of cancer that causes significant amounts of skeletal muscle and body fat loss.
Cancer cachexia can affect your quality of life and may affect the ability to receive cancer treatment. Its prevalence varies across cancer types, ranging from 87% in pancreatic and gastric cancer to 40% in breast cancer, sarcoma, leukemia, and Hodgkin lymphoma. As a secondary disease in cancer patients, cachexia progresses with systemic inflammation, negative protein-energy balance, and involuntary loss of lean body mass. These changes, accompanied by alterations in body composition, contribute to clinical manifestations such as significant weight reduction and disruptions in biological balance. Recognizing these symptoms is crucial for early intervention and management to improve patient outcomes.
Diagnosis typically involves assessing clinical signs such as weight loss exceeding 5% within six months, decreased food intake, reduced muscle strength, and overall decline in functional status. Laboratory tests may reveal abnormalities such as anemia, elevated inflammatory markers, and altered metabolic parameters. Imaging studies can identify tumor burden and potential complications. Importantly, diagnosis requires ruling out other causes of weight loss and muscle wasting. Once diagnosed, management involves a multidisciplinary approach focusing on symptom management, nutritional support, physical activity, and addressing underlying cancer pathology, aiming to improve quality of life and potentially treatment outcomes.
The treatment of cancer cachexia requires a comprehensive, individualized approach focused on improving muscle mass, enhancing overall body state, and increasing tolerance to anti-tumor therapies. While tumors continue to grow, cancer cachexia can be separated from underlying diseases through targeted blockade of cachexia signals, prolonging survival. Palliative treatment strategies are preferred for end-stage cachexia. In cases of catabolically active underlying diseases like advanced lung cancer and bile duct cancer, inhibiting catabolic drugs is the primary treatment choice.
""Cancer Cachexia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cancer Cachexia pipeline landscape is provided which includes the disease overview and Cancer Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cancer Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Cachexia.
This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Cachexia Emerging Drugs
- ACM-001.1: Actimed Therapeutics Ltd
- Ponsegromab: Pfizer
- AV-380: AVEO Pharmaceuticals, Inc.
Further product details are provided in the report……..
Cancer Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cancer Cachexia
- There are approx. 12+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the most advanced stage, i.e. Phase II/III include, Actimed Therapeutics Ltd.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Cancer Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.
Cancer Cachexia Report Insights
- Cancer Cachexia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cancer Cachexia drugs?
- How many Cancer Cachexia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Cachexia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cancer Cachexia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cancer Cachexia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Actimed Therapeutics Ltd
- Pfizer
- AVEO Pharmaceuticals, Inc.
- NGM Biopharmaceuticals
- Endevica Bio
- ACM-001.1
- Ponsegromab
- AV-380
- NGM120
- TCMCB07
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Cancer Cachexia: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Cancer Cachexia– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II/III)
- Comparative Analysis
- ACM-001.1: Actimed Therapeutics Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Ponsegromab: Pfizer
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AV-380: AVEO Pharmaceuticals, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cancer Cachexia Key Companies
- Cancer Cachexia Key Products
- Cancer Cachexia- Unmet Needs
- Cancer Cachexia- Market Drivers and Barriers
- Cancer Cachexia- Future Perspectives and Conclusion
- Cancer Cachexia Analyst Views
- Cancer Cachexia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
